ECNP Award for Negative Results in Clinical Neuroscience

The ECNP Award for Negative Results in Clinical Neuroscience recognises those who have made exceptional contributions to CNS treatment development by publishing clinical research with negative findings. Winners are selected especially on the basis of the impact of their findings in helping the field to optimise its resource and investment allocation and, in doing so, advance long-term treatment development. This is the first year it has been given.

The 2019 award goes to:

  • David Brown
  • Kazuyuki Nakagome
  • Joachim Cordes
  • Ronald Brenner
  • Gerhard Gründer
  • Richard S.E. Keefe
  • Robert Riesenberg
  • David P. Walling
  • Kristen Daniels
  • Lara Wang
  • Jennifer McGinniss
  • Michael Sand

‘Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial’. Click here to read the full article on Schizophrenia Bulletin 45.2, March 2019, pp 350-359.

Michael Sand, Senior Clinical Program Leader CNS at Boehringer Ingelheim Pharmaceuticals in Connecticut, U.S.A., will accept the award at a special award ceremony at the 32nd ECNP Congress on Tuesday 10 September, at 13.30.